| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R43DK134273 | Smartphone image analysis for real time adequacy assessment during kidney biopsy | 000 | 1 | NIH | 1/14/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $933,992 ) |
| | 2024 | 2024 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R44DK138688 | A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases | 001 | 2 | NIH | 8/20/2024 | $950,283 |
| | 2024 | 2023 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R44DK138688 | A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases | 000 | 1 | NIH | 10/26/2023 | $0 |
| | 2024 | 2022 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R43AR081720 | Development of specific peptide reagents for serologic monitoring of Exostosin autoantibodies in membranous lupus nephritis | 000 | 1 | NIH | 7/3/2024 | -$16,291 |
| | 2024 | 2022 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R21AI151491 | Predictive biomarkers of treatment response in kidney transplant rejection | 000 | 2 | NIH | 11/8/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,906,918 ) |
| | 2023 | 2023 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R44DK130702 | Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy | 001 | 3 | NIH | 5/8/2023 | $930,814 |
| | 2023 | 2023 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R44DK138688 | A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases | 000 | 1 | NIH | 9/15/2023 | $976,283 |
| | 2023 | 2022 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R21AI151491 | Predictive biomarkers of treatment response in kidney transplant rejection | 000 | 2 | NIH | 6/9/2023 | -$179 |
| | 2023 | 2022 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R44DK130702 | Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy | 000 | 2 | NIH | 5/1/2023 | $16,605 |
| | 2023 | 2021 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R41DK130702 | Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy | 000 | 1 | NIH | 5/1/2023 | -$16,605 |
| | 2023 | 2021 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R41DK130702 | Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy | 001 | 1 | NIH | 5/15/2023 | -$16,605 |
| | 2023 | 2021 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R41DK130702 | Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy | 002 | 1 | NIH | 6/21/2023 | $16,605 |
| | 2023 | 2021 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R43DK131737 | Rapid Genotyping of ApoL1 Risk Alleles using CRISPR-Cas12a | 000 | 1 | NIH | 9/5/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,878,330 ) |
| | 2022 | 2022 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R21AI151491 | Predictive biomarkers of treatment response in kidney transplant rejection | 003 | 2 | NIH | 5/26/2022 | $212,799 |
| | 2022 | 2022 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R43DK134273 | Smartphone image analysis for real time adequacy assessment during kidney biopsy | 000 | 1 | NIH | 9/12/2022 | $252,144 |
| | 2022 | 2022 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R44DK130702 | Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy | 000 | 2 | NIH | 9/12/2022 | $1,018,450 |
| | 2022 | 2022 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R43AR081720 | Development of specific peptide reagents for serologic monitoring of Exostosin autoantibodies in membranous lupus nephritis | 000 | 1 | NIH | 9/2/2022 | $259,379 |
| | 2022 | 2022 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R21AI151491 | Predictive biomarkers of treatment response in kidney transplant rejection | 000 | 2 | NIH | 1/6/2022 | $135,558 |
|
| Issue Date FY: 2021 ( Subtotal = $500,881 ) |
| | 2021 | 2021 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R41DK130702 | Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy | 000 | 1 | NIH | 7/2/2021 | $247,778 |
| | 2021 | 2021 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R43DK131737 | Rapid Genotyping of ApoL1 Risk Alleles using CRISPR-Cas12a | 000 | 1 | NIH | 9/8/2021 | $253,103 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R43MD014110 | Development of biomarkers for improved classification of membranous lupus nephritis | 000 | 1 | NIH | 9/10/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $300,934 ) |
| | 2019 | 2019 | NEPHROPATHOLOGY ASSOCIATES, PLC | 10810 EXECUTIVE CENTER DR STE 100 | LITTLE ROCK | AR | 72211-4386 | PULASKI | USA | R43MD014110 | Development of biomarkers for improved classification of membranous lupus nephritis | 000 | 1 | NIH | 7/26/2019 | $300,934 |
|
| Issue Date FY: 2014 ( Subtotal = $143,382 ) |
| | 2014 | 2014 | NEPHROPATHOLOGY ASSOCIATES PLC | 10810 EXECUTIVE CENTER DRIVE | LITTLE ROCK | AR | 72211 | PULASKI | USA | R43DK103432 | A Panel-Based Approach to the Diagnosis of Genetic Nephropathies Utilizing Next G | 000 | 1 | NIH | 9/24/2014 | $143,382 |
|
| Issue Date FY: 2005 ( Subtotal = $123,021 ) |
| | 2005 | 2005 | NEPHROPATHOLOGY ASSOCIATES | 10802 EXECUTIVE CENTER DRIVE | LITTLE ROCK | AR | 72211 | PULASKI | USA | R43DK062518 | PREDICTING NEPHROPATHY IN TYPE II DIABETES | 000 | 2 | NIH | 5/13/2005 | $123,021 |
|
| Issue Date FY: 2004 ( Subtotal = $114,789 ) |
| | 2004 | 2004 | NEPHROPATHOLOGY ASSOCIATES | 10802 EXECUTIVE CENTER DRIVE | LITTLE ROCK | AR | 72211 | PULASKI | USA | R43DK062518 | PREDICTING NEPHROPATHY IN TYPE II DIABETES | 000 | 1 | NIH | 4/19/2004 | $114,789 |
|
|
